EGFR and chronic myelogenous leukemia, BCR-ABL1 positive: Among the 11 putative targets, gefitinib, an EGFR inhibitor, was tested in combination with imatinib in K562 CML cell line using MTT cell proliferation assay and was found to have a synergistic antiproliferative activity; EGFR inhibits or reverses imatinib resistance by enhancing the ability of imatinib to bind at the ATP-binding site of Bcr-Abl kinase [40].